Xenon Pharmaceuticals XENE Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's accounts payable?
- Xenon Pharmaceuticals (XENE) reported accounts payable of $38.25M in Q1 2026.
- How has Xenon Pharmaceuticals's accounts payable changed year-over-year?
- Xenon Pharmaceuticals's accounts payable increased by 24.8% year-over-year, from $30.65M to $38.25M.
- What is the long-term trend for Xenon Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's accounts payable has grown at a 29.9% compound annual growth rate (CAGR), from $10.87M to $40.26M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.